These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 38950582

  • 1. The Risk of Medication-Related Osteonecrosis of the Jaw in Children: Guidance for Antiresorptive Use in Pediatric Patients.
    Lasky S, Moshal T, Shakoori P, Roohani I, Jolibois M, Youn S, Urata MM, Hammoudeh JA.
    J Oral Maxillofac Surg; 2024 Oct; 82(10):1285-1294. PubMed ID: 38950582
    [Abstract] [Full Text] [Related]

  • 2. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
    Everts-Graber J, Lehmann D, Burkard JP, Schaller B, Gahl B, Häuselmann H, Studer U, Ziswiler HR, Reichenbach S, Lehmann T.
    J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
    [Abstract] [Full Text] [Related]

  • 3. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T, Van Cann T, Schöffski P, Clement PM, Bechter O, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B.
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [Abstract] [Full Text] [Related]

  • 4. Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.
    Zhang C, Shen G, Li H, Xin Y, Shi M, Zheng Y, Wang M, Liu Z, Zhao Y, Zhao F, Ren D, Zhao J.
    Spec Care Dentist; 2024 Apr; 44(2):530-541. PubMed ID: 37219080
    [Abstract] [Full Text] [Related]

  • 5. Antiresorptive treatment-associated ONJ.
    Eleutherakis-Papaiakovou E, Bamias A.
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702
    [Abstract] [Full Text] [Related]

  • 6. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
    Liu FC, Luk KC, Chen YC.
    Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Drug-induced osteonecrosis of the jaw: the state of the art.
    Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D.
    Reumatismo; 2017 May 22; 69(1):9-15. PubMed ID: 28535616
    [Abstract] [Full Text] [Related]

  • 9. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O.
    Cochrane Database Syst Rev; 2017 Oct 06; 10(10):CD012432. PubMed ID: 28983908
    [Abstract] [Full Text] [Related]

  • 10. A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer.
    Schiodt M, Vadhan-Raj S, Chambers MS, Nicolatou-Galitis O, Politis C, Coropciuc R, Fedele S, Jandial D, Zhang J, Ma H, Saunders DP.
    Support Care Cancer; 2018 Jun 06; 26(6):1905-1915. PubMed ID: 29275525
    [Abstract] [Full Text] [Related]

  • 11. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB.
    Oral Maxillofac Surg Clin North Am; 2015 Nov 06; 27(4):509-16. PubMed ID: 26362367
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
    Jakob T, Tesfamariam YM, Macherey S, Kuhr K, Adams A, Monsef I, Heidenreich A, Skoetz N.
    Cochrane Database Syst Rev; 2020 Dec 03; 12(12):CD013020. PubMed ID: 33270906
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
    Ehrenstein V, Heide-Jørgensen U, Schiødt M, Akre O, Herlofson BB, Hansen S, Larsson Wexell C, Nørholt SE, Tretli S, Kjellman A, Glennane A, Lowe KA, Sørensen HT.
    Cancer; 2021 Nov 01; 127(21):4050-4058. PubMed ID: 34310704
    [Abstract] [Full Text] [Related]

  • 18. Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab.
    Yarom N, Lazarovici TS, Whitefield S, Weissman T, Wasserzug O, Yahalom R.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jan 01; 125(1):27-30. PubMed ID: 29102242
    [Abstract] [Full Text] [Related]

  • 19. What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis?
    Colella A, Yu E, Sambrook P, Hughes T, Goss A.
    J Oral Maxillofac Surg; 2023 Feb 01; 81(2):232-237. PubMed ID: 36442534
    [Abstract] [Full Text] [Related]

  • 20. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug 01; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.